2022 Full-year results and business update
– TG4050: New Phase I data confirms the strong clinical and commercial potential of this highly innovative personalized immunotherapy. Preparing for a Phase II trial in head and neck cancer, which purpose is to provide data for a potential registration.
– TG4001: Positive interim analysis supports continuation of the ongoing randomized Phase II clinical trial. Final results to be reported in 2024. Transgene is preparing for a registration targeting study.
– Oncolytic viruses: New clinical data confirms the potential for Invir.IO® oncolytic viruses to be given via intravenous administration. Launch of the new multi-armed TG6050 aimed at a major solid tumor indication.
– €26.8 million in cash and cash equivalents as of December 31, 2022 – Financial visibility until early 2024.
Conference call in English scheduled today at 6:00 pm CET (details at the end of the release)
…/…